Identification of a Live Attenuated Vaccine Candidate for Tularemia Prophylaxis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Mahawar, Manish ^a   Rabadi, Seham M ^b   Banik, Sukalyani ^b   Catlett, Sally V ^c   Metzger, Dennis W ^a   Malik, Meenakshi ^c   Bakshi, Chandra Shekhar ^a,b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; LIVE VACCINE; MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN A; SODIUM PROTON EXCHANGE PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; BACTERIUM MUTANT; CONTROLLED STUDY; CYTOKINE RESPONSE; FRANCISELLA TULARENSIS; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION CONTROL; INNATE IMMUNITY; MOUSE; MUTAGENESIS; NONHUMAN; SPLEEN CELL; TRANSPOSON; TULAREMIA;

ANIMALS; ANTIBODY FORMATION; BACTERIAL VACCINES; CYTOKINES; FRANCISELLA TULARENSIS; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOLOGIC MEMORY; INFLAMMATION MEDIATORS; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROBIAL VIABILITY; MUTATION; SPLEEN; TULAREMIA; VACCINES, ATTENUATED; VIRULENCE;

FRANCISELLA TULARENSIS; MUS;

EID: 84876239239     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061539     Document Type: Article

References (52)

1. Sjostedt A, (2007) Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 1105: 1-29.
2. Cronquist S, (2004) Tularemia: the disease and the weapon. Dermatol Clin 22: 313-320.
3. Bossi P, Bricaire F, (2003) Tularemia, a potential bioterrorism weapon. Presse Med 32: 1126-1130.
4. Dennis D, Inglesby T, Henderson D, Bartlett J, Ascher M, et al. (2001) Tularemia as a biological weapon: medical and public health management. JAMA 285: 2763-2773.
5. Biennial Review, (2012) Possession, use and transfer of select agents and toxins; Final rule. Federal Register 77: 194.
6. Rawool D, Bitsaktsis C, Li Y, Gosselin D, Lin Y, et al. (2008) Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 180: 5548-5557.
7. Cole L, Yang Y, Elkins K, Fernandez E, Qureshi N, et al. (2009) Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A 106: 4343-4348.
8. Huntley J, Conley P, Rasko D, Hagman K, Apicella M, et al. (2008) Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun 76: 3664-3671.
9. Hickey A, Hazlett K, Kirimanjeswara G, Metzger D, (2011) Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia. Vaccine 29: 6941-6947.
10. Conlan J, (2004) Vaccines against Francisella tularensis-past, present and future. Expert Rev Vaccines 3: 307-314.
11. Waag D, McKee K Jr, Sandstrom G, Pratt L, Bolt C, et al. (1995) Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis. Clin Diagn Lab Immunol 2: 143-148.
12. Saslaw S, Carlisle H, (1961) Studies with tularemia vaccines in volunteers. IV. Brucella aggiutinins in vaccinated and nonvaccinated volunteers challenged with Pasteurella tularensis. Am J Med Sci 242: 166-172.
13. Eigelsbach H, Hornick R, Tulis J, (1967) Recent studies on live tularemia vaccine. Med Ann Dist Columbia 36: 282-286.
14. Hornick R, Eigelsbach H, (1966) Aerogenic immunization of man with live Tularemia vaccine. Bacteriol Rev 30: 532-538.
15. Cowley S, Myltseva S, Nano F, (1996) Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production. Mol Microbiol 20: 867-874.
16. Bakshi C, Malik M, Mahawar M, Kirimanjeswara G, Hazlett K, et al. (2008) An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26: 5276-5288.
17. Sammons-Jackson W, McClelland K, Manch-Citron J, Metzger D, Bakshi C, et al. (2008) Generation and characterization of an attenuated mutant in a response regulator gene of Francisella tularensis live vaccine strain (LVS). DNA Cell Biol 27: 387-403.
18. Pechous R, Celli J, Penoske R, Hayes S, Frank D, et al. (2006) Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Infect Immun 74: 4452-4461.
19. Li J, Ryder C, Mandal M, Ahmed F, Azadi P, et al. (2007) Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology 153: 3141-3153.
20. Twine S, Bystrom M, Chen W, Forsman M, Golovliov I, et al. (2005) A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect Immun 73: 8345-8352.
21. Pechous R, McCarthy T, Mohapatra N, Soni S, Penoske R, et al. (2008) A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS ONE 3: e2487-.
22. Qin A, Scott D, Thompson J, Mann B, (2009) Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect Immun 77: 152-161.
23. Andersson H, Hartmanova B, Kuolee R, Ryden P, Conlan W, et al. (2006) Transcriptional profiling of host responses in mouse lungs following aerosol infection with type A Francisella tularensis. J Med Microbiol 55: 263-271.
24. Rockx-Brouwer D, Chong A, Wehrly T, Child R, Crane D, et al. (2012) Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. PLoS ONE 7: e37752-.
25. Mahawar M, Atianand M, Dotson R, Mora V, Rabadi S, et al. (2012) Identification of a novel Francisella tularensis factor required for intramacrophage survival and subversion of innate immune response. J Biol Chem 287: 25216-25229.
26. Bakshi C, Malik M, Regan K, Melendez JA, Metzger D, et al. (2006) Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. J Bacteriol 188: 6443-6448.
27. Melillo A, Mahawar M, Sellati T, Malik M, Metzger D, et al. (2009) Identification of Francisella tularensis live vaccine strain CuZn superoxide dismutase as critical for resistance to extracellularly generated reactive oxygen species. J Bacteriol 191: 6447-6456.
28. Melillo A, Bakshi C, Melendez J, (2010) Francisella tularensis antioxidants harness reactive oxygen species to restrict macrophage signaling and cytokine production. J Biol Chem 285: 27553-27560.
29. De P, Chou A, Bosio C, Huang C, Follmann D, et al. (2012) Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS. PLoS Pathog 8: e1002494-.
30. Bell J, Owen C, Larson C, (1955) Virulence of Bacterium tularense. I. A study of the virulence of Bacterium tularense in mice, guinea pigs, and rabbits. J Infect Dis 97: 162-166.
31. Chiavolini D, Alroy J, King C, Jorth P, Weir S, et al. (2008) Identification of immunologic and pathologic parameters of death versus survival in respiratory tularemia. Infect Immun 76: 486-496.
32. Griffin K, Oyston P, Titball R, (2007) Francisella tularensis vaccines. FEMS Immunol Med Microbiol 49: 315-323.
33. Landay M, Wright G, Pulliam J, Finegold M, (1968) Toxicity of Pasteurella tularensis killed by ionizing radiation. J Bacteriol 96: 804-810.
34. Huntley J, Conley P, Rasko D, Hagman K, Apicella M, et al. (2008) Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun 76: 3664-3671.
35. Kadull P, Reames H, Coriell L, Foshay L, (1950) Studies on tularemia. V. Immunization of man. J Immunol 65: 425-435.
36. Twine S, Shen H, Harris G, Chen W, Sjostedt A, et al. (2012) BALB/c mice, but not C57BL/6 mice immunized with a DeltaclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses. Vaccine 30: 3634-3645.
37. El Sahly H, Atmar R, Patel S, Wells J, Cate T, et al. (2009) Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine 27: 4905-4911.
38. Kosono S, Haga K, Tomizawa R, Kajiyama Y, Hatano K, et al. (2005) Characterization of a multigene-encoded sodium/hydrogen antiporter (sha) from Pseudomonas aeruginosa: its involvement in pathogenesis. J Bacteriol 187: 5242-5248.
39. Bury-Mone S, Thiberge J, Contreras M, Maitournam A, Labigne A, et al. (2004) Responsiveness to acidity via metal ion regulators mediates virulence in the gastric pathogen Helicobacter pylori. Mol Microbiol 53: 623-638.
40. Weiss D, Brotcke A, Henry T, Margolis J, Chan K, et al. (2007) In vivo negative selection screen identifies genes required for Francisella virulence. Proc Natl Acad Sci U S A 104: 6037-6042.
41. Qin A, Mann B (2006) Identification of transposon insertion mutants of Francisella tularensis tularensis strain Schu S4 deficient in intracellular replication in the hepatic cell line HepG2. BMC Microbiol 6: 69-.
42. Conlan J, Shen H, Webb A, Perry M, (2002) Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20: 3465-3471.
43. Fulop M, Manchee R, Titball R, (1995) Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13: 1220-1225.
44. Su J, Yang J, Zhao D, Kawula T, Banas J, et al. (2007) Genome-wide identification of Francisella tularensis virulence determinants. Infect Immun 75: 3089-3101.
45. Kirimanjeswara G, Golden J, Bakshi C, Metzger D, (2007) Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 179: 532-539.
46. Sebastian S, Pinkham J, Lynch J, Ross R, Reinap B, et al. (2009) Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis. Vaccine 27: 597-605.
47. Collazo C, Meierovics A, De P, Wu T, Lyons C, et al. (2009) T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria. Infect Immun 77: 2010-2021.
48. Shen H, Harris G, Chen W, Sjostedt A, Ryden P, et al. (2010) Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS ONE 5: e13349-.
49. Kuolee R, Harris G, Conlan J, Chen W, (2007) Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine 25: 3781-3791.
50. Khader S, Gopal R, (2010) IL-17 in protective immunity to intracellular pathogens. Virulence 1: 423-427.
51. Lin Y, Ritchea S, Logar A, Slight S, Messmer M, et al. (2009) Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31: 799-810.
52. Paranavitana C, Zelazowska E, Dasilva L, Pittman P, Nikolich M, et al. (2010) Th17 cytokines in recall responses against Francisella tularensis in humans. J Interferon Cytokine Res 30: 471-476.